MRI in Diagnosing Solid Tumors of the Eye and Orbit

Conditions:Cancer, Cancer, Ocular
Therapuetic Areas:Oncology, Ophthalmology
Age Range:18 - Any
Start Date:June 2004
End Date:December 2020
Contact:The Ohio State University Comprehensive Cancer Center

Use our guide to learn which trials are right for you!

Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit.

This study is being done due to a new imaging method that may help others in the future to
improve evaluation of diseases in the eye and eye socket and to help make a decision
concerning best treatment of the disease. Previous studies suggests that dynamic contrast
enhanced MRI is ideally suited to show small structures in the eye and eye socket as well as
to provide information about the eye socket such as blood circulation. This research may also
provide information about the likelihood of the tumor spreading from the eye into other
organs as well as correlate the study images with all other clinical imaging


I. To determine the feasibility of DCE-MRI (dynamic contrast enhanced magnetic resonance
imaging) as non-invasive imaging tool to image contrast enhancement in ocular and orbital

II. To compare contrast enhancement and its distribution within orbital tissue. III. To
assess potential differences in contrast enhancement which help to characterize malignant
lesions as well as discriminate these from benign tissue.

IV. To compare image characteristics between clinical high field end ex-vivo ultra high field
magnetic resonance (MR) imaging.

V. To correlate imaging findings with obtained histology by comparing contrast enhancement
parameters, e.g. maximum signal intensity, to histology characteristics, e.g. vascular


Patients undergo DCE-MRI.

After completion of study treatment, patients are followed up every 6 months for up to 5

Inclusion Criteria:

- The patient has an orbital mass which needs further diagnostic evaluation before
treatment or for monitoring

- Able to give informed consent

- Return for follow-up visits

Exclusion Criteria:

- Patients with a lesion < 2 mm

- The patient should not participate in this study is any of the following applies to
the patient: the patients has a pacemaker, metallic cardiac valve(s), magnetic
material such as surgical clips, implanted electronic infusion pumps or any other
condition that would interfere with the MRI, the patient has a stent somewhere in the
body, the patient has a history of allergic reaction to any metals, contrast agents,
x-ray dyes, the patient has claustrophobia

- Patients cannot be pregnant and prisoners will not be considered for the study

- Exposure to gadolinium-based contrast agents increases the risk for nephrogenic
systemic fibrosis (NSF) in patients with acute or severe renal dysfunction; therefore,
patients with the following conditions are excluded from the study:

- Acute or chronic severe renal insufficiency (glomerular filtration rate < 30
mL/min/1.73 m^2)

- Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative
liver transplantation period

- In order to identify subjects at risk for the development of NSF, the American College
of Radiology ( recommends obtaining a medical history and a glomerular
filtration rate (GFR) assessment within six weeks of MR imaging in the following

- Renal disease (including solitary kidney, renal transplant, renal tumor)

- Age > 60

- History of hypertension

- History of diabetes

- History of severe hepatic disease/liver transplant/pending liver transplant

- All subjects providing written informed consent will complete the subject history and
screening form prior to MR imaging; the form will be reviewed to determine whether the
subject is at risk as defined above and the availability of an estimated glomerular
filtration rate (eGFR) within six weeks of anticipated MR imaging; an eGFR result
greater than six weeks prior to the MRI imaging date will be repeated and evaluated
for renal function; subjects with an eGFR of < 30 mL/min/1.73 m^2 will be excluded
from the study
We found this trial at
Columbus, Ohio 43210
Principal Investigator: Michael V. Knopp, MD
Phone: 614-293-9998
Columbus, OH
Click here to add this to my saved trials